These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28127999)

  • 1. Newborn screening for cystic fibrosis: can one algorithm fit all?
    Caggana M
    Expert Rev Mol Diagn; 2017 Mar; 17(3):205-207. PubMed ID: 28127999
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening.
    Baker MW; Groose M; Hoffman G; Rock M; Levy H; Farrell PM
    J Cyst Fibros; 2011 Jul; 10(4):278-81. PubMed ID: 21388895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving outcomes for Colorado's IRT-IRT-DNA cystic fibrosis newborn screening algorithm by implementing floating cutoffs.
    Martiniano SL; Croak K; Bonn G; Sontag MK; Sagel SD
    Mol Genet Metab; 2021; 134(1-2):65-67. PubMed ID: 34489170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
    Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
    J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
    Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
    J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newborn screening for cystic fibrosis: do we need a second IRT?
    Price JF
    Arch Dis Child; 2006 Mar; 91(3):209-10. PubMed ID: 16492882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of newborn screening for cystic fibrosis in Norway. Results from the first three years.
    Lundman E; Gaup HJ; Bakkeheim E; Olafsdottir EJ; Rootwelt T; Storrøsten OT; Pettersen RD
    J Cyst Fibros; 2016 May; 15(3):318-24. PubMed ID: 26795017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
    Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
    BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive Newborn Screening for Cystic Fibrosis, What to Do Next?
    Kumar P; Goyal JP
    Indian J Pediatr; 2019 Dec; 86(12):1147. PubMed ID: 31325101
    [No Abstract]   [Full Text] [Related]  

  • 11. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
    Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
    J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
    Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
    Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondhand Smoke Exposure and Serum Trypsinogen in Cystic Fibrosis Carriers.
    Ellery KM; Kopp B; Conwell DL; Gariepy C
    Pancreas; 2019 Oct; 48(9):1155-1159. PubMed ID: 31593019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe lung disease in children with cystic fibrosis missed in newborn screening.
    Baldwin K; Barker EM; Carayannopoulos M; Farrell PM; Zanni R; Scanlin TF
    Pediatr Pulmonol; 2024 Jan; 59(1):163-168. PubMed ID: 37888495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of newborn screening for cystic fibrosis in Europe.
    Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
    J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
    Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
    Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn screening for cystic fibrosis.
    Hayes D
    South Med J; 2006 Apr; 99(4):403. PubMed ID: 16634253
    [No Abstract]   [Full Text] [Related]  

  • 18. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.